Page 3 - Clinical Development Programs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

KNOXVILLE, TN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on investigational cancer immunotherapy PV-10 (rose bengal sodium) as an immune vaccine adjuvant will be presented on a poster presentation at the Society for Immunotherapy of Cancer (SITC) 2023 annual meeting to be held in San Diego, CA from November 1-5. This PV-10 research has been led by Aru Narendran, MD, PhD and his team of researchers at the Cumming School o

Dublin, June 22, 2023 (GLOBE NEWSWIRE) -- The "Gene Therapy: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's...

Management's Discussion and Analysis of Financial Condition and Results of Operations is based upon our condensed consolidated financial statements, which have been prepared in accordance with... | May 3, 2023

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

ASH 2022 sponsored programs – UCART123 abstract selected for oral presentation & preclinical data on UCARTCS1 selected for poster presentation, in...